Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors (LASI)

Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of Genitourinary Syndrome of Menopause (GSM) in Patients Using Aromatase Inhibitors: Double Blinded Randomized Controlled Clinical Trial.

To study the efficacy and safety of intravaginal CO2 laser versus intravaginal Er:YAG laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast cancer

Study Overview

• Status: Recruiting
• Conditions: Genitourinary Syndrome of Menopause
• Intervention / Treatment: Device: intravaginal laser

Detailed Description

The objective is to compare microablative fractional CO2 laser (CO2 laser) (SmartXide2 V2 LR, Monalisa Touch; DEKA, Florence, Italy) and non-ablative photothermal Erbium:YAG laser (Er:YAG laser) (Fotona Smooth™ XS; Fotona, Ljubljana, Slovenia) - with sham vaginal applications for treatment of vaginal dryness as the leading symptom in breast cancer patients with iatrogenic menopause and treated with an AI.

• Study Type: Interventional
• Enrollment (Estimated): 162
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Susanne Housmans, MD; Phone Number: +3216332211; Email: susanne.housmans@uzleuven.be
• Study Contact Backup: Name: Jan Deprest, PhD; Phone Number: +3216332211; Email: jan.deprest@uzleuven.be

Study Locations

• Belgium
  • Flemish Brabant
    • Leuven, Flemish Brabant, Belgium, 3000
      • Recruiting
      • UZ Leuven
      • Contact: Susanne Housmans, MD; Phone Number: +3216332211; Email: susanne.housmans@uzleuven.be
      • Contact: Jan Deprest, PhD; Phone Number: +3216332211; Email: jan.deprest@uzleuven.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Recruited participants will meet all of these criteria:

• a history of breast cancer
• premenopausal at diagnosis of breast cancer
• using AI as an adjuvant treatment
• moderate to severe symptoms of GSM (VAS ≥ 4/10)
• currently menopausal, which can be either biochemical menopause as confirmed after chemotherapy, surgical or medicinally induced (GnRH analogues for the duration of the trial)

Exclusion Criteria:

• Not willing to abstain from vaginal intercourse for 1 week following laser therapy
• Use of non-hormonal vaginal preparations within the last 6 weeks before inclusion
• Use of hormonal therapy within 6 months prior to inclusion (systemic or local)
• Acute urinary or genital tract infections
• A history of genital fistula, a thin rectovaginal septum as determined by the investigator, or history of fourth degree laceration
• Prolapse ≥ grade 2 according to the Pelvic Organ Prolapse Quantification System
• Previous vaginal mesh implantation
• Abnormal result in the last cervical smear (maximum 36 month before enrollment)
• Active cancer treatment (radiotherapy or chemotherapy) ongoing or planned prior to the measurement of the primary outcome (6 months after inclusion, 3 months after last laser)
• Vaginal stenosis that does not allow the placement of the laser probe
• Any condition that could interfere with study compliance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Mona Lisa Touch CO2 laser; Power: 30 W.; Dwell time: 1000 μs.; Spacing: 1000 μm.; Depth: SmartStack parameter from 1 to 3 depending on the treatment status.; D-pulse mode.; At the introitus the power will be reduced to 24 W	Device: intravaginal laser; application of intravaginal laser
Active Comparator: Fotona Smooth erbium:YAG laser; Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.; Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 10 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm.	Device: intravaginal laser; application of intravaginal laser
Sham Comparator: sham treatment; The blocking device is inserted over the laser outlet before attaching the application speculum. With this device the laser beam is blocked entirely.; Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.; Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 1,5 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm.	Device: intravaginal laser; application of intravaginal laser

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change in severity dryness as most bothersome symptom (MBS) of GSM at 3 months after the end of treatment	scored on a 10 cm VAS	at 3 months after the end of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient reported effect of laser on other GSM symptoms	scored on a 10 cm VAS	at 3 months after the end of treatment
Female Sexual Function Index (FSFI)	measured with FSFI questionnaire. The cut-off score of >26,55 will be used to discriminate between women with impaired and unimpaired sexual functioning	at 3 months after the end of treatment
Urinary Distress Index (UDI-6)	Measured with UDI-6 questionnaire	at 3 months after the end of treatment
The degree of discomfort of the treatment procedure by the participant	scored on a 10 cm VAS	at the end of the each treatment-visit
The longevity of the effect	Determined by questioning the need the participant feels for repeat treatment, and its nature (repeat laser or alternatives) until two years after the end of treatment.	at 24 months after the end of treatment
Vaginal pH	Measured with a pH indicator strip (range 3.6-6.1) and is sampled from the lateral vaginal wall in the lower third of the vagina	at 3 months after the end of treatment
Vaginal Health Index Score (VHIS)	Scoring of vaginal moisture, vaginal fluid volume, vaginal elasticity, vaginal pH, and vaginal epithelial integrity on a scale of 1 (poorest) to 5 (best) according to the methods of Robert Wood Johnson Medical School. The lower the score, the greater the atrophy. Vaginal moisture is an assessment of the appearance and spread or consistency of the secretions which coat the vagina. Vaginal elasticity is a measure of the ability of the vaginal tissue to stretch from the examiner's finger. Vaginal epithelial integrity takes into account color, thickness, and ability of the tissue to resist breaking secondary to touch.	at 3 months after the end of treatment
Vaginal Maturation Value (VMV)	A vaginal smear will be obtained from the lateral vaginal wall using a spatula and will be stained according to the Papanicolaou technique. The Vaginal Maturation Index (VMI) is evaluated by defining the proportion of superficial, intermediate, and parabasal epithelial cells on the smear. To combine this information into a single score for quantifying estrogenization, the VMV was calculated. It is based on weighted proportions of cell types from the VMI and calculated using Meisels' formula: the percentage of superficial cells (S) plus 0.5 times the percentage of intermediate cells (I) coded from the cytology sample [MV= %S + (0.5 × % I)	at 3 months after the end of treatment
Description of adverse events	Adverse events are questioned at each visit following an intravaginal treatment.	until 1 month after the last treatment visit

Collaborators and Investigators

• Sponsor: Universitaire Ziekenhuizen KU Leuven
• Investigators: Principal Investigator: Susanne Housmans, MD, UZ Leuven

Study record dates

Study Major Dates

• Study Start (Actual): December 27, 2022
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: January 9, 2023
• First Submitted That Met QC Criteria: January 26, 2023
• First Posted (Actual): February 6, 2023

Study Record Updates

• Last Update Posted (Actual): July 1, 2024
• Last Update Submitted That Met QC Criteria: June 28, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: breast cancer; aromatase inhibitor; genitourinary syndrome of menopause; intravaginal laser
• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Syndrome
• Other Study ID Numbers: S66520

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No